Nicolas Andre

List of Publications by Year
in descending order

125 papers	4,756 citations	117571 34 h-index	110317 64 g-index
136 all docs	136 docs citations	136 times ranked	6172 citing authors

#	Article	IF	Citations
1	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro-Oncology, 2022, 24, 153-165.	0.6	28
2	Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers, 2022, 14, 374.	1.7	16
3	The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. Cancer Discovery, 2022, 12, 1266-1281.	7.7	67
4	Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. Current Oncology, 2022, 29, 1902-1918.	0.9	5
5	Sixâ€month BNT162b2 vaccine efficacy in adolescents and young adults with cancer. Pediatric Blood and Cancer, 2022, 69, e29547.	0.8	0
6	Trametinib for a BRAF G469A missense mutation in a neuroblastoma unveiled by liquid biopsy. Pediatric Blood and Cancer, 2022, 69, .	0.8	2
7	Blood-Derived Liquid Biopsies Using Foundation OneÂ® Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience. Cancers, 2022, 14, 2774.	1.7	6
8	Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a modelâ€based population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology, 2022, 90, 29-44.	1.1	2
9	Description of a giant hypothalamic hamartoma associated with an immature ruptured giant sacrococcygeal teratoma: a case report. Child's Nervous System, 2021, 37, 2363-2367.	0.6	0
10	Impact of COVIDâ€19 on cancer care: A survey from the French Society of Pediatric Oncology (SFCE). Pediatric Blood and Cancer, 2021, 68, e28554.	0.8	8
11	Development and Validation of a Prediction Model of Overall Survival in High-Risk Neuroblastoma Using Mechanistic Modeling of Metastasis. JCO Clinical Cancer Informatics, 2021, 5, 81-90.	1.0	12
12	A sport room within the paediatric oncology ward. Ecancermedicalscience, 2021, 15, ed108.	0.6	0
13	Favorable Outcome of COVID-19 Infection in a Pediatric Cancer Patient Receiving an Anti-PD-L1/Anti-CTLA-4 Combination. Journal of Pediatric Hematology/Oncology, 2021, 43, e1045-e1046.	0.3	2
14	Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data. Lancet Oncology, The, 2021, 22, 595-596.	5.1	3
15	Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 2239.	1.7	15
16	Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSÃ©-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer, 2021, 150, 53-62.	1.3	33
17	Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Lancet, The, 2021, 398, 278-279.	6.3	5
18	Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSÃ©-ESMART Trial. Journal of Clinical Oncology, 2021, 39, 3546-3560.	0.8	17

#	Article	IF	Citations
19	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	2.7	12
20	The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. European Journal of Cancer, 2021, 154, 30-34.	1.3	45
21	Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population. European Journal of Cancer, 2021, 156, 125-126.	1.3	1
22	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncology, The, 2021, 22, 1416-1426.	5.1	93
23	First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSÃ©-ESMART trial. European Journal of Cancer, 2021, 157, 268-277.	1.3	19
24	A Randomized Trial of Physical Activity in Children and Adolescents with Cancer. Cancers, 2021, 13, 121.	1.7	16
25	Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5. Neuro-Oncology, 2021, 23, 1163-1172.	0.6	23
26	Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse. Journal of Pediatric Hematology/Oncology, 2021, 43, e630-e634.	0.3	7
27	Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary lowâ€grade glioma. British Journal of Clinical Pharmacology, 2021, , .	1.1	3
28	Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma. Neuro-Oncology Advances, 2021, 3, vdab169.	0.4	11
29	Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas. Neuro-Oncology, 2020, 22, 128-138.	0.6	22
30	Metroâ€SMHOP 01: Metronomics combination with cyclophosphamideâ€etoposide and valproic acid for refractory and relapsing pediatric malignancies. Pediatric Blood and Cancer, 2020, 67, e28508.	0.8	6
31	Covidâ€19: Breaking bad news with social distancing in pediatric oncology. Pediatric Blood and Cancer, 2020, 67, e28524.	0.8	5
32	Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report from the French Society of Pediatric Oncology. Cancers, 2020, 12, 3398.	1.7	26
33	Machine Learning Approach to Forecast Chemotherapy-Induced Haematological Toxicities in Patients with Rhabdomyosarcoma. Cancers, 2020, 12, 1944.	1.7	9
34	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	1.3	15
35	SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. Cancers, 2020, 12, 3051.	1.7	4
36	COVIDâ€19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms?. Pediatric Blood and Cancer, 2020, 67, e28392.	0.8	74

#	Article	IF	Citations
37	Challenges and opportunities for cancer clinical trials in low- and middle-income countries. Nature Cancer, 2020, 1, 142-145.	5.7	18
38	Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All. Trends in Cancer, 2020, 6, 819-828.	3.8	20
39	Metronomic Chemotherapy for Children in Low- and Middle-Income Countries: Survey of Current Practices and Opinions of Pediatric Oncologists. Journal of Global Oncology, 2019, 5, 1-8.	0.5	5
40	Metronomic Maintenance Therapy for Rhabdomyosarcoma. Trends in Cancer, 2019, 5, 756-759.	3.8	5
41	SFCE METROâ€01 fourâ€drug metronomic regimen phase II trial for pediatric extracranial tumor. Pediatric Blood and Cancer, 2019, 66, e27693.	0.8	6
42	Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. Therapeutic Drug Monitoring, 2019, 41, 142-159.	1.0	9
43	Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.. Journal of Clinical Oncology, 2019, 37, 10018-10018.	0.8	3
44	AcSÃ©-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescentsâ€“Arm D: Olaparib and irinotecan.. Journal of Clinical Oncology, 2019, 37, 10047-10047.	0.8	5
45	Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. European Respiratory Review, 2018, 27, 170098.	3.0	21
46	Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas. Ecancermedicalscience, 2018, 12, 862.	0.6	11
47	Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial. Frontiers in Pharmacology, 2018, 9, 00950.	1.6	15
48	ATRT-16. CONGENITAL RHABDOID TUMORS AS A MAJOR CLINICAL CHALLENGE - A COLLABORATIVE EUROPEAN EFFORT. Neuro-Oncology, 2018, 20, i30-i31.	0.6	0
49	â€œHardâ€•Drug Repurposing for Precision Oncology: The Missing Link?. Frontiers in Pharmacology, 2018, 9, 637.	1.6	22
50	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600â€“mutant relapsed refractory low-grade glioma.. Journal of Clinical Oncology, 2018, 36, 10506-10506.	0.8	17
51	Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?. Trends in Cancer, 2017, 3, 319-325.	3.8	52
52	Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression. Scientific Reports, 2017, 7, 45136.	1.6	21
53	A French retrospective study on clinical outcome in 102 choroid plexus tumors in children. Journal of Neuro-Oncology, 2017, 135, 151-160.	1.4	35
54	Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy. Cancer Research, 2017, 77, 4723-4733.	0.4	36

#	Article	IF	Citations
55	Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report. Frontiers in Pharmacology, 2017, 8, 792.	1.6	10
56	Necrotic ulcerated and bleeding striae distensae following bevacizumab in a palliative setting for gliobastomatosis cerebri. Ecancermedicalscience, 2017, 11, 756.	0.6	3
57	Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget, 2017, 8, 2874-2889.	0.8	58
58	Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients. Oncotarget, 2017, 8, 47161-47166.	0.8	26
59	On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach. Mathematical Biosciences and Engineering, 2017, 14, 217-235.	1.0	20
60	Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27â€“28 May, 2016, Rosario, Argentina. Ecancermedicalscience, 2016, 10, 672.	0.6	9
61	Next generation metronomic chemotherapyâ€”report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€“8 May 2016, Mumbai. Ecancermedicalscience, 2016, 10, 689.	0.6	10
62	Metronomics during palliative care in paediatric oncology? For sure! ButÂhandle me with care. Acta Paediatrica, International Journal of Paediatrics, 2016, 105, 874-875.	0.7	3
63	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	3.9	478
64	Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumabâ€“irinotecan in children with lowâ€grade glioma?. Cancer Medicine, 2016, 5, 1542-1545.	1.3	15
65	Pharmacokinetics and Pharmacogenetics of Metronomics. , 2016, , 189-207.		0
66	A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. BMC Cancer, 2016, 16, 278.	1.1	22
67	Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. Cancer Research, 2016, 76, 4931-4940.	0.4	132
68	Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. EBioMedicine, 2016, 6, 87-95.	2.7	100
69	Metronomics â€” fulfilling unmet needs beyond level A evidence. Nature Reviews Clinical Oncology, 2016, 13, 469-470.	12.5	5
70	Computational oncology â€” mathematical modelling of drug regimens for precision medicine. Nature Reviews Clinical Oncology, 2016, 13, 242-254.	12.5	174
71	Embryonal tumors with multilayered rosettes in children: the SFCE experience. Child's Nervous System, 2016, 32, 299-305.	0.6	46
72	Future paradigms for precision oncology. Oncotarget, 2016, 7, 46813-46831.	0.8	23

#	Article	IF	Citations
73	Pilot evaluation of physical and psychological effects of a physical trek programme including a dog sledding expedition in children and teenagers with cancer. Ecancermedicalscience, 2015, 9, 558.	0.6	3
74	Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. Ecancermedicalscience, 2015, 9, 499.	0.6	46
75	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. Seminars in Cancer Biology, 2015, 35, 53-61.	4.3	67
76	Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect. Oncotarget, 2015, 6, 23008-23014.	0.8	23
77	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 463.	0.6	26
78	Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch. Frontiers in Oncology, 2014, 4, 76.	1.3	31
79	Metronomic Chemotherapy Regimens Using Microtubule-Targeting Agents: Mechanisms of Action, Preclinical Activity and Future Developments. , 2014, , 69-90.		0
80	Metronomics chemotherapy: time for computational decision support. Cancer Chemotherapy and Pharmacology, 2014, 74, 647-652.	1.1	37
81	Metronomics: towards personalized chemotherapy?. Nature Reviews Clinical Oncology, 2014, 11, 413-431.	12.5	263
82	Embryonal tumor with multilayered rosettes: Diagnostic tools update and review of the literature. , 2014, 33, 15-22.		38
83	Metronomic Chemotherapy. , 2014, , 2809-2811.		0
84	Metronomic Chemotherapy. , 2014, , 1-3.		0
85	Metronomics: Potential Social Impact and New Business Models to Improve Availability of Cancer Treatments. , 2014, , 247-261.		0
86	Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathologica Communications, 2013, 1, 17.	2.4	17
87	Has the time come for metronomics in low-income and middle-income countries?. Lancet Oncology, The, 2013, 14, e239-e248.	5.1	142
88	Investment in cancer studies in countries of low and middle income. Lancet, The, 2013, 382, 684.	6.3	5
89	Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis, 2013, 16, 373-386.	3.7	50
90	Can Targeted Therapy be Successful without Metronomic Scheduling ?. Current Topics in Medicinal Chemistry, 2012, 12, 1639-1642.	1.0	7

#	Article	IF	Citations
91	Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma â€“ A report from the SociÃ©tÃ© FranÃ§aise des Cancers et leucÃ©mies de lâ€™Enfant et de lâ€™adolescent (SFCE). European Journal of Cancer, 2012, 48, 2409-2416.	4.3	57
92	Neurocognitive function after radiotherapy for paediatric brain tumours. Nature Reviews Neurology, 2012, 8, 578-588.	4.9	111
93	Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends. Pediatric Blood and Cancer, 2012, 59, 34-38.	0.8	45
94	SKIV2L Mutations Cause Syndromic Diarrhea, or Trichohepatoenteric Syndrome. American Journal of Human Genetics, 2012, 90, 689-692.	2.6	139
95	Pediatric Pleural Mesothelioma. Pediatric Oncology, 2012, , 231-237.	0.5	0
96	Paediatric Peritoneal Mesothelioma. Pediatric Oncology, 2012, , 313-319.	0.5	0
97	Integrating pharmacogenetics into gemcitabine dosingâ€”time for a change?. Nature Reviews Clinical Oncology, 2011, 8, 439-444.	12.5	63
98	Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Translational Oncology, 2011, 4, 203-211.	1.7	35
99	Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?. Future Oncology, 2011, 7, 385-394.	1.1	41
100	Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget, 2011, 2, 960-965.	0.8	61
101	Reirradiation and Concomitant Metronomic Temozolomide. Journal of Pediatric Hematology/Oncology, 2011, 33, 600-604.	0.3	26
102	Children Treated With Metronomic Chemotherapy in a Low-income Country. Journal of Pediatric Hematology/Oncology, 2011, 33, 31-34.	0.3	37
103	Novel mutations in TTC37 associated with tricho-hepato-enteric syndrome. Human Mutation, 2011, 32, 277-281.	1.1	52
104	Looking at the Seemingly Contradictory Role of Vinblastine in Anaplastic Large-Cell Lymphoma From a Metronomic Perspective. Journal of Clinical Oncology, 2011, 29, e90-e91.	0.8	7
105	Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget, 2011, 2, 797-809.	0.8	189
106	Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatric Blood and Cancer, 2010, 54, 616-617.	0.8	21
107	Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?. Pediatric Blood and Cancer, 2010, 54, 781-782.	0.8	5
108	Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies. Journal of Clinical Oncology, 2010, 28, 160-165.	0.8	115

#	Article	IF	Citations
109	Anti-Angiogenic Therapies for Children with Cancer. Current Cancer Drug Targets, 2010, 10, 879-889.	0.8	6
110	Metronomic chemotherapy: new rationale for new directions. Nature Reviews Clinical Oncology, 2010, 7, 455-465.	12.5	553
111	Metronomic chemotherapy: Back to the future!. Drug News and Perspectives, 2010, 23, 143.	1.9	11
112	Retrospective comparison of neutropenia in children with ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF. Clinical Therapeutics, 2009, 31, 2388-2395.	1.1	14
113	Low dose cytarabine in patients with relapsed or refractory Ewing sarcoma. Pediatric Blood and Cancer, 2009, 53, 238-238.	0.8	10
114	Metronomic chemotherapyâ€induced bilateral subdural hematoma in a child with meningeal carcinomatosis. Pediatric Blood and Cancer, 2009, 53, 246-247.	0.8	6
115	For cancer, seek and destroy or live and let live?. Nature, 2009, 460, 324-324.	13.7	17
116	Exclusion of EGFR, HRAS, DSP, JUP, CTNNB1, PLEC1, and EPPK1 as Functional Candidate Genes in 7 Families With Syndromic Diarrhoea. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 501-503.	0.9	3
117	Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'. Nature Clinical Practice Oncology, 2009, 6, E1-E1.	4.3	14
118	Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: A preliminary monocentric study. Clinical Therapeutics, 2008, 30, 1336-1340.	1.1	35
119	Safety of Pegfilgrastim in Children. Annals of Pharmacotherapy, 2008, 42, 290-290.	0.9	5
120	FDG PET and Evaluation of Posttherapeutic Residual Tumors in Pediatric Oncology: Preliminary Experience. Journal of Pediatric Hematology/Oncology, 2008, 30, 343-346.	0.3	6
121	Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment. Current Cancer Drug Targets, 2007, 7, 566-581.	0.8	124
122	Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anti-Cancer Drugs, 2007, 18, 277-281.	0.7	32
123	Intractable diarrhea with â€œphenotypic anomaliesâ€•and tricho-hepato-enteric syndrome: Two names for the same disorder. American Journal of Medical Genetics, Part A, 2007, 143A, 584-588.	0.7	35
124	Atypical teratoid rhabdoid tumor in a child with neurofibromatosis 1. Pediatric Blood and Cancer, 2006, 46, 267-268.	0.8	8
125	Molecular effects of cyclosporine and oncogenesis: a new model. Medical Hypotheses, 2004, 63, 647-652.	0.8	45